Affimed (NASDAQ:AFMD) Short Interest Down 14.9% in March

Affimed (NASDAQ:AFMD) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 602,500 shares, a drop of 14.9% from the February 28th total of 708,100 shares. Based on an average daily volume of 186,000 shares, the short-interest ratio is currently 3.2 days. Approximately 4.6% of the company’s shares are short sold.

Institutional Investors Weigh In On Affimed

A number of hedge funds and other institutional investors have recently modified their holdings of AFMD. Northern Trust Corp purchased a new position in Affimed in the fourth quarter valued at $218,000. Intellectus Partners LLC boosted its position in shares of Affimed by 34.0% during the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Affimed in the 3rd quarter valued at about $44,000. Point72 Asset Management L.P. raised its position in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Finally, FMR LLC raised its position in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares in the last quarter. 30.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Affimed in a research report on Tuesday, December 10th. StockNews.com initiated coverage on Affimed in a report on Tuesday. They issued a “sell” rating on the stock. Finally, Wells Fargo & Company reduced their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $0.71 on Thursday. Affimed has a fifty-two week low of $0.69 and a fifty-two week high of $8.95. The firm’s 50 day moving average price is $0.96 and its 200 day moving average price is $2.03. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.